The pharmaceutical industry in 2024 faced a relatively quiet year, with deal volumes similar to 2023 but lower deal values, ...

Dipan Mehta of Elixir Equities notes that the Trump presidency and earnings season will be major market trends in 2025.

Both companies are longtime leaders in the pharmaceutical industry and have been making breakthroughs and delivering ...

Acadia’s 50-day moving average is in the process of crossing above the stock’s 200-day moving average. This crossover forms a ...

Sumeet Bagadia, Executive Director at Choice Broking has recommended M&M, Sun Pharma, and Dalmia Bharat as the top three ...

Immedica Pharma AB, a global rare disease company will acquire Marinus Pharmaceuticals (NASDAQ:MRNS) by means of a tender ...

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...

Jefferies analyst Dennis Ding initiated coverage of Rhythm Pharmaceuticals (RYTM) with a Buy rating and $80 price target Don't Miss Our New ...

Parekh recommends purchasing the stock at Rs 38 with a target of Rs 42 and a stop loss at Rs 36. Over the past year, the ...

Stocks that were in focus include names like SAIL, which rose 4% and Aurobindo Pharma, which gained 1% and HPCL, whose shares ...

Jefferies analyst Dennis Ding initiated coverage of Rhythm Pharmaceuticals (RYTM) with a Buy rating and $80 price target The firm sees an ...